Dual functional bioactive-peptide, AIMP1-derived peptide (AdP), for anti-aging.


Journal

Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964

Informations de publication

Date de publication:
Feb 2019
Historique:
accepted: 02 04 2018
pubmed: 20 6 2018
medline: 14 6 2019
entrez: 20 6 2018
Statut: ppublish

Résumé

Human skin aging is caused by several factors, such as UV irradiation, stress, hormone, and pollution. Wrinkle formation and skin pigmentation are representative features of skin aging. Although EGF and arbutin are used as anti-wrinkle and skin whitening agents, respectively, they have adverse effects on skin. When more cosmeceutical ingredients are added to cosmetic product, adverse effects are also accumulated. For these reasons, multifunctional and safe cosmetic ingredients are in demand. The aim of the present study is to investigate the novel anti-aging agents, AIMP1-derived peptide (AdP, INCI name: sh-oligopeptide-5/sh-oligopeptide SP) for cosmetic products. To assess the anti-wrinkle effect of AdP, collagen type I synthesis and fibroblast proliferation were determined on human fibroblasts. The anti-wrinkle effect of AdP was examined by ELISA and cell titer glo assay. To assess the whitening, melanin content and tyrosinase activity were determined on melanocytes. The whitening effect of AdP was examined by melanin measurement and enzyme activity assay. The safety of AdP was determined by cytotoxicity and immunogenicity, CCK-8 and TNF-α ELISA assay, respectively. AdP treatment induced the collagen type I synthesis and fibroblast proliferation. Also, AdP treatment inhibited melanin synthesis by regulating tyrosinase activity. The anti-aging effect of AdP is more potent than EGF and albutin. AdP did not show adverse effects. These results show that AdP can be dual functional and safe cosmeceutical agent to prevent skin aging.

Sections du résumé

BACKGROUND BACKGROUND
Human skin aging is caused by several factors, such as UV irradiation, stress, hormone, and pollution. Wrinkle formation and skin pigmentation are representative features of skin aging. Although EGF and arbutin are used as anti-wrinkle and skin whitening agents, respectively, they have adverse effects on skin. When more cosmeceutical ingredients are added to cosmetic product, adverse effects are also accumulated. For these reasons, multifunctional and safe cosmetic ingredients are in demand. The aim of the present study is to investigate the novel anti-aging agents, AIMP1-derived peptide (AdP, INCI name: sh-oligopeptide-5/sh-oligopeptide SP) for cosmetic products.
METHODS METHODS
To assess the anti-wrinkle effect of AdP, collagen type I synthesis and fibroblast proliferation were determined on human fibroblasts. The anti-wrinkle effect of AdP was examined by ELISA and cell titer glo assay. To assess the whitening, melanin content and tyrosinase activity were determined on melanocytes. The whitening effect of AdP was examined by melanin measurement and enzyme activity assay. The safety of AdP was determined by cytotoxicity and immunogenicity, CCK-8 and TNF-α ELISA assay, respectively.
RESULTS RESULTS
AdP treatment induced the collagen type I synthesis and fibroblast proliferation. Also, AdP treatment inhibited melanin synthesis by regulating tyrosinase activity. The anti-aging effect of AdP is more potent than EGF and albutin. AdP did not show adverse effects.
CONCLUSION CONCLUSIONS
These results show that AdP can be dual functional and safe cosmeceutical agent to prevent skin aging.

Identifiants

pubmed: 29921010
doi: 10.1111/jocd.12671
doi:

Substances chimiques

Collagen Type I 0
Cosmeceuticals 0
Cytokines 0
Melanins 0
Neoplasm Proteins 0
Peptides 0
RNA-Binding Proteins 0
Skin Lightening Preparations 0
Tumor Necrosis Factor-alpha 0
small inducible cytokine subfamily E, member 1 0
Monophenol Monooxygenase EC 1.14.18.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

251-257

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Jina Kim (J)

Cure Bio Co., Ltd. Research Center, Suwon-si, Korea.

Sujin Kang (S)

Cure Bio Co., Ltd. Research Center, Suwon-si, Korea.

HanJin Kwon (H)

UltraV Co., Ltd. Research Center, Seoul, Korea.

HoSang Moon (H)

UltraV Co., Ltd. Research Center, Seoul, Korea.

Min Chul Park (MC)

Cure Bio Co., Ltd. Research Center, Suwon-si, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH